A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.

NCT05776927 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

304

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: QVM149
DRUG: Salmeterol Xinafoate / Fluticasone Propionate
DRUG: Placebo to QVM149
DRUG: Placebo to Salmeterol Xinafoate / Fluticasone Propionate
DRUG: Run-In Medication
DRUG: Rescue Medication
DEVICE: Concept 1 Device
DEVICE: Girohaler

Sponsor

Novartis Pharmaceuticals